{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:18:34Z","timestamp":1781885914507,"version":"3.54.5"},"reference-count":35,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>(1) Background: The primary objective of this study was to examine the rate of genetic referral, BRCA testing, and BRCA positivity amongst all patients with high-grade serous ovarian cancers (HGSOC) from 2004\u20132019. The secondary objective was to analyze secondary factors that may affect the rates of referral and testing. (2) Methods: This population-based cohort study included all women diagnosed with HGSOC using the Manitoba Cancer Registry, CervixCheck registry, Medical Claims database at Manitoba Health, the Hospital Discharge abstract, the Population Registry, and Winnipeg Regional Health Authority genetics data. Data were examined for three different time cohorts (2004\u20132013, 2014\u20132016; 2017\u20132019) correlating to practice pattern changes. (3) Results: A total of 944 patients were diagnosed with HGSOC. The rate of genetic referrals changed over the three timeframes (20.0% \u2192 56.7% \u2192 36.6%) and rate of genetic testing increased over the entire timeframe. Factors found to increase rates of referral and testing included age, histology, history of oral contraceptive use, and family history of ovarian cancer. Prior health care utilization indicators did not affect genetic referral or testing. (4) Conclusion: The rate of genetic referral (2004\u20132016) and BRCA1\/2 testing (2004\u20132019) for patients with a diagnosis of HGSOC increased over time. A minority of patients received a consultation for genetics counselling, and even fewer received testing for a BRCA1\/2. Without a genetic result, it is difficult for clinicians to inform treatment decisions. Additional efforts are needed to increase genetics consultation and testing for Manitoban patients with HGSOC. Effects of routine tumour testing on rates of genetic referral will have to be examined in future studies.<\/jats:p>","DOI":"10.3390\/curroncol29120735","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T08:46:41Z","timestamp":1669798001000},"page":"9365-9376","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Referral, Genetic Counselling, and BRCA Testing in the Manitoba High-Grade Serous Ovarian Cancer Population, 2004\u20132019"],"prefix":"10.3390","volume":"29","author":[{"given":"Kelcey","family":"Winchar","sequence":"first","affiliation":[{"name":"Obstetrics, Gynecology and Reproductive Sciences, University of Manitoba, Winnipeg, MB R3A 1R9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Lambert","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, MB R3E OV9, Canada"},{"name":"Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, MB R3E OV9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0081-8737","authenticated-orcid":false,"given":"Kirk J.","family":"McManus","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, MB R3E OV9, Canada"},{"name":"Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB R3E OV9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernie","family":"Chodirker","sequence":"additional","affiliation":[{"name":"Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB R3E OV9, Canada"},{"name":"Pediatrics and Child Health (Section of Genetics and Metabolism), University of Manitoba, Winnipeg, MB R3E OV9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kean","sequence":"additional","affiliation":[{"name":"Obstetrics, Gynecology and Reproductive Sciences, University of Manitoba, Winnipeg, MB R3A 1R9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Serfas","sequence":"additional","affiliation":[{"name":"Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB R3E OV9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0044-7545","authenticated-orcid":false,"given":"Kathleen","family":"Decker","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, MB R3E OV9, Canada"},{"name":"Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, MB R3E OV9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3291-8628","authenticated-orcid":false,"given":"Mark W.","family":"Nachtigal","sequence":"additional","affiliation":[{"name":"Obstetrics, Gynecology and Reproductive Sciences, University of Manitoba, Winnipeg, MB R3A 1R9, Canada"},{"name":"CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, MB R3E OV9, Canada"},{"name":"Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB R3E OV9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6345-4910","authenticated-orcid":false,"given":"Alon D.","family":"Altman","sequence":"additional","affiliation":[{"name":"Obstetrics, Gynecology and Reproductive Sciences, University of Manitoba, Winnipeg, MB R3A 1R9, Canada"},{"name":"CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, MB R3E OV9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/IGC.0000000000000148","article-title":"Improving referral for genetic risk assessment in ovarian cancer using an electronic medical record system","volume":"24","author":"Petzel","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.humpath.2005.06.006","article-title":"Hereditary ovarian cancer","volume":"36","author":"Prat","year":"2005","journal-title":"Hum. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation\u2013Positive Women with Ovarian Cancer: A Report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/IGC.0000000000000689","article-title":"Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing","volume":"26","author":"Cohen","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/IGC.0000000000000907","article-title":"Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario","volume":"27","author":"McGee","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10897-012-9553-3","article-title":"Acceptance of genetic counseling and testing in a hospital-based series of patients with gynecological cancer","volume":"22","author":"Dekker","year":"2013","journal-title":"J. Genet. Couns."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1002\/cncr.28183","article-title":"A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value","volume":"119","author":"Lu","year":"2013","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/OGX.0b013e3181e62f2d","article-title":"Evaluating Women with Ovarian Cancer for BRCA1 and BRCA2 Mutations Missed Opportunities","volume":"65","author":"Meyer","year":"2010","journal-title":"Obstet. Gynecol. Surv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.ygyno.2015.04.029","article-title":"Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetics professionals","volume":"138","author":"Febbraro","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/IGC.0b013e318280f2b4","article-title":"Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling?","volume":"23","author":"Powell","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_19","unstructured":"Hotes Ellison, J., Wu, X.C., McLaughlin, C., Lake, A., Firth, R., and Cormier, M.E. (2006). Incidence. Cancer in North America: 1999\u20132003, NAACCR."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_21","unstructured":"Fransoo, R., Martens, P., Burland, E., Prior, H., Burchill, C., Chateau, D., and Walld, R. (2005). Sex Differences in Health Status, Health Care Use, and Quality of Care: A Population-Based Analysis for Manitoba\u2019s Regional Health Authorities. Manit. Cent. Health Policy, Available online: http:\/\/mchp-appserv.cpe.umanitoba.ca\/reference\/sexdiff.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1097\/IGC.0000000000001074","article-title":"Examining the Effects of Time to Diagnosis, Income, Symptoms, and Incidental Detection on Overall Survival in Epithelial Ovarian Cancer: Manitoba Ovarian Cancer Outcomes (MOCO) Study Group","volume":"27","author":"Altman","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygyno.2017.01.030","article-title":"Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics","volume":"145","author":"Kentwell","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s11606-010-1334-9","article-title":"Familial Risk of Cancer and Knowledge and Use of Genetic Testing","volume":"25","author":"Baer","year":"2010","journal-title":"J. Gen. Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.fertnstert.2011.11.007","article-title":"Knowledge and attitudes regarding expanded genetic carrier screening among women\u2019s healthcare providers","volume":"97","author":"Ready","year":"2012","journal-title":"Fertil. Steril."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s13187-010-0063-4","article-title":"Obstetrics\/Gynecology Residents\u2019 Knowledge of Hereditary Breast and Ovarian Cancer and Lynch Syndrome","volume":"25","author":"Ready","year":"2010","journal-title":"J. Cancer Educ."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2354.2008.01065.x","article-title":"BRCA testing of breast cancer patients: Medical specialists\u2019 referral patterns, knowledge and attitudes to genetic testing","volume":"19","author":"Verhoef","year":"2010","journal-title":"Eur. J. Cancer. Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/jmg.2004.030296","article-title":"Hereditary breast\/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians","volume":"42","author":"Wideroff","year":"2005","journal-title":"J. Med. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s10897-013-9598-y","article-title":"Genetic risk assessment for women with epithelial ovarian cancer: Referral patterns and outcomes in a university gynecologic oncology clinic","volume":"22","author":"Petzel","year":"2013","journal-title":"J. Genet. Couns."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.2013.51.3226","article-title":"Randomized Noninferiority Trial of Telephone Versus In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer","volume":"32","author":"Schwartz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_32","first-page":"1251","article-title":"Factors associated with decisions about clinical BRCA1\/2 testing","volume":"9","author":"Armstrong","year":"2000","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1023\/A:1009451213035","article-title":"Factors Influencing Patients\u2019 Decisions to Decline Cancer Genetic Counseling Services","volume":"10","author":"Geer","year":"2001","journal-title":"J. Genet. Couns."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/gte.2006.9998","article-title":"Factors Associated with an Individual\u2019s Decision to Withdraw from Genetic Testing for Breast and Ovarian Cancer Susceptibility: Implications for Counseling","volume":"11","author":"Godard","year":"2007","journal-title":"Genet. Test."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ygyno.2011.09.002","article-title":"Endometrial cancer patients and compliance with genetic counseling: Room for improvement","volume":"123","author":"Backes","year":"2011","journal-title":"Gynecol. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/12\/735\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:30:14Z","timestamp":1760146214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/12\/735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["curroncol29120735"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29120735","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]}}}